Proactiveinvestors recommends
Additional Information
Market: LSE
Sector: Pharmaceuticals & Biotechnology
EPIC: RNVO
Latest Price: 19.13p  (1.32% Ascending)
52-week High: 19.75p
52-week Low: 16.50p
Market Cap: 28.62M
1 year chart More charts
digital-look imported chart image
Deal RNVO Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
digital-look imported chart image
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Renovo Group Plc
www.renovo.com
Deal Renovo Group Plc Tax Free* Losses can exceed
your initial deposit *subject to change and depends on individual circumstances.

Renovo (LSE:RNVO) is a biopharmaceutical product company and a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. 

Full Renovo Group Plc profile here
Pdf

Renovo ends Prevascar development

April 16 2012, 11:59am The clinical trial results follow the disappointing results of the Juvista trial in February 2011

Renovo (LON:RNVO) today confirmed that it will now perform any further work on Prevascar following the completion of a clinical trial.

The company says that it will continue to focus on its merger and acquisition plans and its share buy-back programme as a way to enhance shareholder value.

The clinical trial results follow the disappointing results of the Juvista trial in February 2011. Subsequently, Renovo’s remaining trials which had already been contracted had continued.

Today, Renovo reported that 56 patients were enrolled in the trial of the Prevascar scar treatment. It said there was a ‘small but significant’ reduction in scar width compared to placebo after one month, however by month 12 there was in fact a ‘small but significant’ improvement in the placebo scar width compared to Prevascar. 

Meanwhile, most other assessments showed no difference between treatments. 

In November, Renove told investors that it was considering all options to maximise value including acquisitions and mergers of external companies.

 

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.